A Preliminary Trial Of Serratiopeptidase In Patients With Carpal Tunnel Syndrome
| Effect | Decrease |
| Trial Design | Cohort |
| Trial Length | 1-6 months |
| Number of Subjects | 20 |
| Sex | Both Genders |
| Age Range | 30-44, 45-64 |
| Body Types | Overweight |
Supplementation of serrapeptase (20mg) daily after an initial course of nimesulide was able to reduce symptoms of carpal tunnel syndrome in 65% of patients studied, but this trial failed to have a placebo group (and even then, is confounded by the initial course of nimesulide).
